ArticleInflammation2021
The enzymatic poly(gallic acid) reduces pro-inflammatory cytokines in vitro, a potential application in inflammatory diseases.
Article in Inflammation, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 46 citations in OpenAlex.
- Article
- Enzymatic Poly(gallic acid)-grafted L-Histidine Reduces Cell Inflammation and Oxidative Stress: In Silico and In Vitro Studies.Chemistry & biodiversity · 2026Article
- Article
- Antimicrobial and immunomodulatory activity of natural bioactive compounds - anFrontiers in immunology · 2025Article
- Gut microbiota and its metabolites promote painful diabetic peripheral neuropathy complicated with cognitive dysfunction in mice.Frontiers in cellular and infection microbiology · 2025Article
- Preparation of gallic acid-loaded chitosan nanoparticles and their chemoprotective effects on N-ethyl-N-nitrosourea-induced hepatotoxicity and mortality in rats.Journal of molecular histology · 2024Article
- In vitro study of the treatment of dentin hypersensitivity with gallic acid combined with sodium fluoride.BMC oral health · 2024Article
- Antiphagocytic Properties of Polygallic Acid with Implications in Gouty Inflammation.Inflammation · 2023Article
- Plausibility of natural immunomodulators in the treatment of COVID-19-A comprehensive analysis and future recommendations.Heliyon · 2023Review
- Gallic acid diminishes pro-inflammatory interferon-γ- and interleukin-17-producing sub-populations in vitro in patients with psoriasis.Immunologic research · 2023Article
- Enhanced mild-temperature photothermal therapy by pyroptosis-boosted ATP deprivation with biodegradable nanoformulation.Journal of nanobiotechnology · 2023Article
- Engineered nanomaterials enhance drug delivery strategies for the treatment of osteosarcoma.Frontiers in pharmacology · 2023Review
- Article
- Anti-inflammatory and Antioxidant Effect of Poly-gallic Acid (PGAL) in an In Vitro Model of Synovitis Induced by Monosodium Urate Crystals.Inflammation · 2022Article
- Gallic Acid Alleviates Visceral Pain and Depression via Inhibition of P2X7 Receptor.International journal of molecular sciences · 2022Article
- IgG subclass and Fc glycosylation shifts are linked to the transition from pre- to inflammatory autoimmune conditions.Frontiers in immunology · 2022Review
- High-Throughput Identification of Organic Compounds from Polygoni Multiflori Radix Praeparata (Molecules (Basel, Switzerland) · 2021Article
- Calming the Storm: Natural Immunosuppressants as Adjuvants to Target the Cytokine Storm in COVID-19.Frontiers in pharmacology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 4 institutions in 1 country.
Funding
Abstract
Cytokines like IL-6, TNF-α, and IL-1β are important mediators of inflammation in many inflammatory diseases, as well as in cellular processes like cell proliferation and cell adhesion. Finding new molecules that decrease cell proliferation, adhesion (inflammatory infiltrate), and pro-inflammatory cytokine release could help in the treatment of many inflammatory diseases. The naturally derived poly(gallic acid) (PGAL), produced enzymatically from gallic acid in aqueous medium, is a non-toxic, thermostable multiradical polyanion that is antioxidant and has potential biomedical uses. Experimental evidence has demonstrated that PGAL reduces pro-inflammatory cytokines, which are the target of some inflammatory diseases. PGAL decreased IL-6, TNF-α, and IL-1β production in human monocytes exposed to PMA without affecting cell viability. Additionally, PGAL reduced cell proliferation by affecting the transition from the S phase to the G2 phase of the cell cycle. Cell adhesion experiments showed that PMA-induced cell adhesion was diminished with the presence of PGAL, particularly at a concentration of 200 μg/mL. These properties of PGAL show a potential use for treating inflammatory diseases, such as psoriasis or arthritis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.